Background And Study Aims: The aim of this study is to present the mortality trends of oesophageal cancer (EC) in the Iranian population, to provide updated information regarding time trends for this cancer.

Patients And Methods: We analysed the national death statistics reported by the Iranian Ministry of Health and Medical Education from 1995 to 2004. EC [International Classification of Diseases (ICD-9); C15] were expressed as the annual mortality rates/100000, overall, by sex and by age group (<15, 15-49 and ≥ 50 years of age) and age standardised rate (ASR).

Results: The age standardised mortality rate of EC increased dramatically during the study period. EC mortality was higher for males and the mortality rate also increased with age.

Conclusion: This study provides a comprehensive projection for the burden of death due to EC, indicating that the trend of EC mortality dramatically increased in the recent decade.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajg.2012.06.008DOI Listing

Publication Analysis

Top Keywords

oesophageal cancer
8
increased oesophageal
4
cancer mortality
4
mortality rate
4
rate iran
4
iran background
4
background study
4
study aims
4
aims aim
4
aim study
4

Similar Publications

Inherited genetics represents an important contributor to risk of esophageal adenocarcinoma (EAC), and its precursor Barrett's esophagus (BE). Genome-wide association studies have identified ∼30 susceptibility variants for BE/EAC, yet genetic interactions remain unexamined. To address challenges in large-scale G×G scans, we combined knowledge-guided filtering and machine learning approaches, focusing on genes with (A) known/plausible links to BE/EAC pathogenesis (n=493) or (B) prior evidence of biological interactions (n=4,196).

View Article and Find Full Text PDF

An Editorial on Salvage Esophagectomy for Esophageal Cancer.

Ann Surg Oncol

January 2025

Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

View Article and Find Full Text PDF

Background And Purpose: It remains unclear whether the lymph-node ratio (LNR) is a relevant factor for the risk of recurrence following neoadjuvant chemotherapy (nCT) with docetaxel, cisplatin, and 5-fluorouracil (DCF), which is a new standard of care for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan. This study aimed to evaluate the clinical utility of LNR as a risk factor for recurrence.

Materials And Methods: We retrospectively analyzed 75 patients who underwent nCT-DCF followed by curative surgery for resectable ESCC.

View Article and Find Full Text PDF

Background: Malignant esophageal mediastinal fistula is a severe complication that occurs in both the advanced stages of esophageal cancer and after radiotherapy for esophageal cancer. Esophageal mediastinal fistula is very susceptible to complications such as mediastinitis and mediastinal abscess, resulting in a significantly elevated mortality rate for patients. We reported a rare case of esophageal mediastinal fistula after immunotherapy for non-small cell lung cancer (NSCLC).

View Article and Find Full Text PDF

Defining the optimal radiation-induced lymphopenia metric to discern its survival impact in esophageal cancer.

Int J Radiat Oncol Biol Phys

January 2025

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, United States of America; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands.

Background: A detrimental association between radiation-induced lymphopenia (RIL) and oncologic outcomes in esophageal cancer patients has been established. However, an optimal metric for RIL remains undefined, but is important for application of this knowledge in clinical decision-making and trial designs. The aim of this study was to find the optimal RIL metric discerning survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!